Interstitial Lung Disease

That this House recognises the urgent need to improve the experience of people with Interstitial Lung Disease (ILD) and Pulmonary Fibrosis, a progressive and life-limiting lung disease affecting over 70,000 people in the UK; acknowledges the impact of the disease on patients, their families, and caregivers, including significant physical, emotional, and financial burdens; notes the current variation in access to timely diagnosis, specialist care, and support services, which can result in inequities in patient outcomes; welcomes the ILD Care Pathway developed by OneVoiceILD, supported by Action for Pulmonary Fibrosis, which is designed to free up overstretched capacity in specialist ILD centres to allow for faster expert diagnosis of ILD, and help ensure better quality care closer to patients’ homes; and calls on the Government to work with NHS England, devolved health services, healthcare professionals, and patient organisations to urgently implement the ILD Care Pathway.